Skip to main content
OpenTrials
Completed

NCT Number: NCT04531410

NETwork of Linoleic Acid Supplementation in Cystic Fibrosis

Undernutrition is a common problem in patients with cystic fibrosis (CF) despite international consensus that the patients shall be given 120-200% of energy recommendations. Studies imply that one problem might be that the patients are not compensated for the essential fatty acid deficiency (linoleic acid, LA), which is well known in these patients. This deficiency is shown not to be due to fat malabsorption, but related to an increased turnover of arachidonic acid, a transformation product of LA. This abnormality is related to mutations associated with a more severe clinical phenotype. The most common and typical symptom of LA deficiency is poor growth. Studies in animals have further indicated that many of the symptoms in CF are related to the deficiency. A series of recent prospective studies from Wisconsin corroborate the importance of LA for growth. In Sweden LA has been supplemented to most patients since the late 70´, and the condition of patients have been among the leading in the world regarding growth, pulmonary function and survival. Short-term studies have shown better effect of LA supplementation compared to similar supply of energy without including extra LA. There are few long-term studies, performed before the gene was identified, giving very heterogeneous patient groups in regard to genotype, but with some positive results on growth and physiology. It´s of interest that modern personalized extremely expensive therapy with correctors and potentiators for Cystic Fibrosis Transmembrane Conductance Regulator may influence lipid metabolism. LA might thus tentatively be a cheap adjuvant to this modern therapy, but this has to be specially studied.

The aim of the study is to find if there are differences in clinical and metabolic outcome between two groups, blindly given similar amount of extra calories, in one group consisting of linoleic acid.The benefit for the patients would be great if the expected positive effect can be proved in the planned study. The treatment will be cheap and without adverse effects. From socioeconomic point of view is would be a great advantage.

Completed

Looking for future studies?

Notify Me

Key information

Age range

5 year–15 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Università degli Studi di Milan, Milan, Italy

Loading trial locations.

About this study

Two group of matched children with CF were randomized to two type of oils given 20 g oil and 600 mg DHA daily for one year and anthropometry, pulmonary function, biochemistry, resting energy expenditure, lipid mediators, inflammatory and intestinal markers were studied at start and at 6 months and 1 year. Dietary intake was controlled and life quality recording at start and end of study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Two mutations related to severe clinical status such as dF508, or other stop mutations or class II mutations. Severe status includes pancreatic insufficiency

Exclusion criteria

  • Liver cirrhosis and/or portal hypertension, transplantation or on transplantation list, intake of lipid supplements the latest 2 months

Treatment and study plan

linoleic acid supplementation

Dietary Supplement

Oils given daily at morning meal with extra enzymes

oleic acid supplementation

Dietary Supplement

Oils given at morning meal with extra enzymes

Primary outcomes

  1. Growth

    Time frame: 1 year

    change in BMI, standard deviation score (SDS)

  2. Weight

    Time frame: 1 year

    change in SDS body weight

  3. Height

    Time frame: 1 year

    change in SDS height

Secondary outcomes

  1. Pulmonary function

    Time frame: 1 year

    change in forced expiratory volume in one second (FEV1 % of predicted)

  2. Quality of life, the patient experience of well being

    Time frame: 1 year

    Questionaire about health, physical activity, well being (8 items), CFQ-child + CFQ- parents (higher rates are better) The score changes are analysed.The CFQ considers the physical, image, digestive, respiratory, emotional, social, food, treatment, vitality, health, social role and weight domains. Each domain has a score and its sum generates the total score, whose values can vary from 0 to 100 The scores will also be related to measurements.

Other outcomes

  1. Lipid mediators

    Time frame: 1 year

    change in lipid mediators in blood and urine, ion trap- Mass Spectrometry, picoMol (> 150 products of both the n-6 and n-3 series)

  2. Clinical infectious status

    Time frame: 1 year

    change in number exacerbations compare to previous year,

  3. Influence on sodium status

    Time frame: 1 year

    change in Sodium in sweat test, mol/L and urine (fractional sodium excretion)

  4. Inflammatory markers

    Time frame: 1 year

    change in Cytokines, Proximity extension assays (PEA proteomics) picogram/ml

  5. Metabolic marker

    Time frame: 1 year

    Change in serum insulin growth factor -1 (IGF-1, nanogram/ml)

  6. Energy metabolism

    Time frame: 1 year

    Change in resting energy expenditure (REE/kg body weight)

  7. Bone mineral density

    Time frame: 1 year

    Change in total bone mineral density by dual x-ray absorptiometry (DXA), gram/cm^2

  8. Oral glucose tolerance

    Time frame: 1 year

    Measure of glucose and insuline after oral glucose loading

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

  • European Society of Pediatric Gastroenterology, Hepatology and Nutrition

Registry information

Official study title

Double-blind Randomized Controlled Study of Linoleic Acid Supplementation for 1 Year in Patients With Cystic Fibrosis - Influence on Clinical Status and Metabolism

Acronym: NETLACF

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Aug 28, 2020
Registry last updated
Nov 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.